tetano
Editor, Senior Moderator
Clin Mol Allergy
. 2022 Dec 22;20(1):15.
doi: 10.1186/s12948-022-00180-1.
The correlation between IgM and IgG antibodies with blood profile in patients infected with severe acute respiratory syndrome coronavirus
Zahra Alibolandi[SUP] 1 2 [/SUP], Amirreza Ostadian[SUP] 1 2 [/SUP], Saeed Sayyah[SUP] 1 2 [/SUP], Hamed Haddad Kashani[SUP] 3 4 [/SUP], Hassan Ehteram[SUP] 1 5 [/SUP], Hamid Reza Banafshe[SUP] 6 [/SUP], Mohammad Hajijafari[SUP] 7 [/SUP], Mahdi Sepehrnejad[SUP] 1 2 [/SUP], Narjes Riahi Kashani[SUP] 1 2 [/SUP], Mohammd-Javad Azadchehr[SUP] 8 [/SUP], Hossein Nikzad[SUP] 1 2 [/SUP], Elahe Seyed Hosseini[SUP] 9 10 [/SUP]
Affiliations
Abstract
Objectives: This study aimed to determine the levels of IgM and IgG antibody response to the severe acute respiratory syndrome coronavirus (SARS-CoV)-2 in coronavirus disease 2019 (COVID-19) patients with different disease severity.
Methods: IgM and IgG antibody levels were evaluated via enzyme-linked immunosorbent assay (ELISA). In total, 100 patients with confirmed SARS-CoV-2 infection were enrolled in this study and viral RNA was detected by using Real-time PCR technique. Clinical and laboratory data were collected and analyzed after hospital admission for COVID-19 and two months post-admission.
Results: The level of anti-SARS-CoV-2 antibody IgG was significantly higher in the severe patients than those in moderate and mild groups, 2 months after admission. Also, level of IgG was positively associated with increased WBC, NUT and LYM counts in sever than mild or moderate groups after admission to hospital.
Conclusion: Our findings suggested that patients with severe illness might experience longer virus exposure times and have a stronger antibody response against viral infection. Thus, they have longer time immunity compared with other groups.
Keywords: COVID-19; IgG; IgM; Illness severity; SARS-CoV-2.
. 2022 Dec 22;20(1):15.
doi: 10.1186/s12948-022-00180-1.
The correlation between IgM and IgG antibodies with blood profile in patients infected with severe acute respiratory syndrome coronavirus
Zahra Alibolandi[SUP] 1 2 [/SUP], Amirreza Ostadian[SUP] 1 2 [/SUP], Saeed Sayyah[SUP] 1 2 [/SUP], Hamed Haddad Kashani[SUP] 3 4 [/SUP], Hassan Ehteram[SUP] 1 5 [/SUP], Hamid Reza Banafshe[SUP] 6 [/SUP], Mohammad Hajijafari[SUP] 7 [/SUP], Mahdi Sepehrnejad[SUP] 1 2 [/SUP], Narjes Riahi Kashani[SUP] 1 2 [/SUP], Mohammd-Javad Azadchehr[SUP] 8 [/SUP], Hossein Nikzad[SUP] 1 2 [/SUP], Elahe Seyed Hosseini[SUP] 9 10 [/SUP]
Affiliations
- PMID: 36550478
- DOI: 10.1186/s12948-022-00180-1
Abstract
Objectives: This study aimed to determine the levels of IgM and IgG antibody response to the severe acute respiratory syndrome coronavirus (SARS-CoV)-2 in coronavirus disease 2019 (COVID-19) patients with different disease severity.
Methods: IgM and IgG antibody levels were evaluated via enzyme-linked immunosorbent assay (ELISA). In total, 100 patients with confirmed SARS-CoV-2 infection were enrolled in this study and viral RNA was detected by using Real-time PCR technique. Clinical and laboratory data were collected and analyzed after hospital admission for COVID-19 and two months post-admission.
Results: The level of anti-SARS-CoV-2 antibody IgG was significantly higher in the severe patients than those in moderate and mild groups, 2 months after admission. Also, level of IgG was positively associated with increased WBC, NUT and LYM counts in sever than mild or moderate groups after admission to hospital.
Conclusion: Our findings suggested that patients with severe illness might experience longer virus exposure times and have a stronger antibody response against viral infection. Thus, they have longer time immunity compared with other groups.
Keywords: COVID-19; IgG; IgM; Illness severity; SARS-CoV-2.